Hikal Ltd
Stock Snapshot
Price Performance
Vista Outlook
Basis of our Recommendation
Hikal Ltd is navigating a pivotal transition, shifting from a two-division structure to a more diversified four-division model, which includes Pharmaceuticals, Crop Protection, Animal Health, and Personal Care. Management's cautious optimism stems from recent capital investments aimed at enhancing capabilities in high-value contract development and manufacturing organization (CDMO) partnerships. This strategic pivot is expected to drive revenue growth, particularly as regulatory hurdles are cleared and new capacities are optimized. However, the Crop Protection segment faces challenges from raw material volatility and pricing pressures, which could impact margins in the near term. Vista's financial outlook reflects a recovery in revenue growth, albeit with anticipated margin pressures, aligning with management's focus on disciplined execution and operational efficiency. The broader industry context supports Hikal's strategy, as the Pharma APIs and CRAMS sector is experiencing expanding growth, driven by increasing demand for outsourcing and favorable regulatory shifts. Over the next 12-24 months, key opportunities include leveraging India's position in global supply chains and capturing demand from the China Plus One trend, while watchpoints include ongoing FDA remediation efforts and geopolitical risks that could disrupt supply chains
Why We Like This Stock
- Transition to a four-division model enhances diversification and growth potential
- Strategic investments in high-value CDMO capabilities are expected to drive revenue recovery
- Favorable industry dynamics and regulatory shifts support Hikal's long-term growth strategy
Things To Watch Out For
- Ongoing U.S. FDA remediation poses risks to operational stability and market confidence
- Raw material volatility and pricing pressures in the Crop Protection segment may impact margins
- Geopolitical tensions could disrupt supply chains and affect operational efficiency
Key Parameters
Financial Snapshot
View Technicals Analysis →| Actuals | Forecast | ||||
|---|---|---|---|---|---|
| FY24 | FY25 | FY26 | FY27 | FY28 | |
| Revenue (Cr.) | 1,785 | 1,860 | 1,713 | 1,802 | 1,922 |
| Profit Before Tax (Cr.) | 95 | 124 | 7 | 21 | 19 |
| PBT Margin | 5.3% | 6.7% | 0.4% | 1.1% | 1.0% |
| Net Profit (Cr.) | 68 | 94 | 33 | 16 | 14 |
| Earnings Per Share | 5.5 | 7.6 | 2.7 | 1.3 | 1.1 |
Analyst Recommendations
No analyst recommendations available.
Company Overview
Show Company Profile
Hikal Limited, together with its subsidiaries, manufactures and sells various chemical intermediates, specialty chemicals, and active pharma ingredients to pharmaceutical, biotechnology, life sciences, animal health, crop protection, and specialty chemicals indusries. It operates through two segments, Pharmaceuticals and Crop Protection. The company also manufactures pesticides and herbicides, which include diuron tech, temephos tech, thiacloprid tech, clothianidin tech, dichloroaniline, N-bromosuccinimide, prothioconazole technical, trifloxystrobin technical, and BIT. In addition, it offers solutions in contract research, custom synthesis, and custom manufacturing of intermediates and active ingredients. Further, the company provides anti-convulsant, anti-inflammatory, analgesic, Anti-parasitic, anti-lipemic, anti-histaminic, anti-depressant, anti-psychotic, anti-emetic, anti-diabetic, anti-thrombotic, Anti-viral, anti-hypertensive, and Haemorheologic; animal health products, such as anti-tick, anti-parasitic, analgesic, anabolic steroids, female sex hormone, insecticide, and NSAID; and specialty biocides and antimicrobial actives, as well as additives for leather, paint coatings, paper, water treatment, personal care, building materials, and textile industries. The company also exports its products. It operates in India, the United States, Canada, Europe, South East Asia, and internationally. The company was formerly known as Hikal Chemical Industries Ltd. and changed its name to Hikal Limited in April 2000. Hikal Limited was incorporated in 1988 and is headquartered in Navi Mumbai, India.